In the featured article in the December issue of Nature Reviews Cancer, Dr. Graham describes the emerging field of TAM family kinases and their potential as therapeutic targets in leukemia and other forms of cancer.
Speaking at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, Dr. Pollyea summarized the latest results for AG-120, an exciting new drug for the treatment of patients with advanced leukemia.
Israel has the highest BRCA+ prevalence of any nation. Rabinovitch will deliver lectures and collaborate with health professionals who have expertise with the BRCA+ population in Israel.
We are very pleased to announce that Dr. Manali Kamdar will be joining us in late November as a new attending physician and Assistant Professor in the Division of Hematology.
"If patients are having difficulties taking their medications, I want to provide the physicians with strategies to help their patients stay on schedule," says Brewer.
Read how the Blood Cancer program's Christine Frodella and other nurse navigators support patients at the University of Colorado Cancer Center
81-year-old Larry Rosenberg credits an experimental drug with saving his life from chronic lymphocytic leukemia. Now the Break Through Therapy Provision will help other patients get faster access to experimental drugs as well.
KCBO radio interview with our patient Emily about her experience with blood cancer. Her doctors treated her for an aggressive form of leukemia.
Psychological wellness of cancer patients often influences health outcomes. Jennifer Caspari spends much of her time building relationships with patients, especially those involved with stem cell transplants, to help their recovery.
Larry Rosenberg is a leukemia patient. Dan Pollyea, MD, is treating Rosenberg. And Michael Bennet is a U.S. senator from Colorado who helped fast-track a drug that is helping Rosenberg and patients like him.